Literature DB >> 2158432

Mechanisms of homologous and heterologous regulation of parathyroid hormone receptors in the rat osteosarcoma cell line UMR-106.

J Mitchell1, D Goltzman.   

Abstract

We have examined the mechanisms of homologous and heterologous regulation of PTH receptor binding and receptor-mediated adenylate cyclase activity in the osteosarcoma cell line UMR-106. Pretreatment with PTH resulted in a time- and dose-dependent decrease in PTH-stimulated adenylate cyclase which was maximal after 2 h and at a concentration of 10(-8) M rat (r)PTH-(1-34). PTH pretreatment over the same dose range also diminished receptor binding of 125I-labeled rPTH-(1-34); however, maximal loss of binding required 14 h and was greater than the loss of maximal adenylate cyclase activity. After 24 h pretreatment with rPTH-(1-34), cell surface receptors were decreased from 21,000 sites per cell to 2,700 sites per cell, and these down-regulated PTH receptors could not be detected in either vesicular or cytosolic subcellular fractions. Recovery from such homologous down-regulation appeared to require new receptor synthesis. Heterologous down-regulation of PTH receptors was demonstrated when UMR-106 cells were preincubated with prostaglandin E2 or (Bu)2cAMP. Heterologous desensitization was shown to be the result of a reversible modification of the PTH receptor which decreased binding affinity and decreased PTH-stimulated adenylate cyclase. Postreceptor components were also examined, and PTH but not prostaglandin E2 pretreatment was shown to decrease guanyl nucleotide binding (G) protein-mediated adenylate cyclase stimulation. This decrease in G protein function was associated with a loss of cholera toxin-catalyzed ADP ribosylation and was also detected by immunoblotting. These results indicate that PTH responses in osteoblastic cells are modulated by diverse mechanisms involving modifications both to the receptor and to postreceptor components of adenylate cyclase.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2158432     DOI: 10.1210/endo-126-5-2650

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

1.  Role of PTH1R internalization in osteoblasts and bone mass using a phosphorylation-deficient knock-in mouse model.

Authors:  Nabanita S Datta; Tareq A Samra; Chandrika D Mahalingam; Tanuka Datta; Abdul B Abou-Samra
Journal:  J Endocrinol       Date:  2010-10-07       Impact factor: 4.286

2.  Specific down-regulation of parathyroid hormone (PTH) receptors and responses to PTH by tumour necrosis factor alpha and retinoic acid in UMR 106-06 osteoblast-like osteosarcoma cells.

Authors:  H G Schneider; E H Allan; J M Moseley; T J Martin; D M Findlay
Journal:  Biochem J       Date:  1991-12-01       Impact factor: 3.857

3.  Regulation of PTH/PTH-related protein receptor expression by endogenous PTH-related protein in the rat osteosarcoma cell line ROS 17/2.8.

Authors:  P Du; P K Seitz; C W Cooper
Journal:  Endocrine       Date:  2000-02       Impact factor: 3.633

4.  Anabolic effects of PTH in cyclooxygenase-2 knockout osteoblasts in vitro.

Authors:  Shilpa Choudhary; Hechang Huang; Lawrence Raisz; Carol Pilbeam
Journal:  Biochem Biophys Res Commun       Date:  2008-05-21       Impact factor: 3.575

5.  Icariin, but Not Genistein, Exerts Osteogenic and Anti-apoptotic Effects in Osteoblastic Cells by Selective Activation of Non-genomic ERα Signaling.

Authors:  Ming-Xian Ho; Christina C-W Poon; Ka-Chun Wong; Zuo-Cheng Qiu; Man-Sau Wong
Journal:  Front Pharmacol       Date:  2018-05-11       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.